A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Clinical trial NCT06271837 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06271837
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Start date: 2024-02-22
Primary completion: 2025-11-28
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.